Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom. more
Time Frame | VRAX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.33% | 0.31% | -1.26% |
1-Month Return | 48.7% | 0.6% | -4.16% |
3-Month Return | 26.52% | -9.44% | -0.46% |
6-Month Return | 102.65% | -5.15% | 3.58% |
1-Year Return | 120.19% | 0.33% | 22.47% |
3-Year Return | -98.74% | 4.53% | 25.13% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 99.88K | 123.82K | - | 8.56K | 156.42K | [{"date":"2020-03-31","value":63.85,"profit":true},{"date":"2021-03-31","value":79.16,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":5.47,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Cost of Revenue | 54.13K | 133.25K | - | 9.93K | 105.83K | [{"date":"2020-03-31","value":40.62,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":7.45,"profit":true},{"date":"2024-03-31","value":79.42,"profit":true}] |
Gross Profit | 45.75K | (9.43K) | - | (1.36K) | 50.59K | [{"date":"2020-03-31","value":90.43,"profit":true},{"date":"2021-03-31","value":-18.65,"profit":false},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-2.7,"profit":false},{"date":"2024-03-31","value":100,"profit":true}] |
Gross Margin | 45.81% | (7.62%) | - | (15.94%) | 32.34% | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-16.63,"profit":false},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-34.81,"profit":false},{"date":"2024-03-31","value":70.61,"profit":true}] |
Operating Expenses | 696.99K | 635.10K | 1.73M | 5.73M | 6.55M | [{"date":"2020-03-31","value":10.65,"profit":true},{"date":"2021-03-31","value":9.7,"profit":true},{"date":"2022-03-31","value":26.48,"profit":true},{"date":"2023-03-31","value":87.54,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Income | (651.24K) | (644.54K) | (1.73M) | (5.73M) | (6.50M) | [{"date":"2020-03-31","value":-65124400,"profit":false},{"date":"2021-03-31","value":-64454000,"profit":false},{"date":"2022-03-31","value":-173368000,"profit":false},{"date":"2023-03-31","value":-573276000,"profit":false},{"date":"2024-03-31","value":-649647300,"profit":false}] |
Total Non-Operating Income/Expense | (178.91K) | (57.02K) | (31.63K) | 259.53K | (269.52K) | [{"date":"2020-03-31","value":-68.94,"profit":false},{"date":"2021-03-31","value":-21.97,"profit":false},{"date":"2022-03-31","value":-12.19,"profit":false},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":-103.85,"profit":false}] |
Pre-Tax Income | (739.46K) | (672.91K) | (1.75M) | (5.46M) | (6.74M) | [{"date":"2020-03-31","value":-73946400,"profit":false},{"date":"2021-03-31","value":-67291500,"profit":false},{"date":"2022-03-31","value":-174987000,"profit":false},{"date":"2023-03-31","value":-545776300,"profit":false},{"date":"2024-03-31","value":-673912000,"profit":false}] |
Income Taxes | 61.67K | (666.47K) | (1.77M) | (271.00) | (194.47K) | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-1080.75,"profit":false},{"date":"2022-03-31","value":-2877.91,"profit":false},{"date":"2023-03-31","value":-0.44,"profit":false},{"date":"2024-03-31","value":-315.36,"profit":false}] |
Income After Taxes | (801.13K) | (6.45K) | 24.85K | (5.46M) | (6.54M) | [{"date":"2020-03-31","value":-3223.61,"profit":false},{"date":"2021-03-31","value":-25.94,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-21959.97,"profit":false},{"date":"2024-03-31","value":-26334.48,"profit":false}] |
Income From Continuous Operations | (739.46K) | (672.91K) | (1.75M) | (5.46M) | (6.74M) | [{"date":"2020-03-31","value":-73946400,"profit":false},{"date":"2021-03-31","value":-67291500,"profit":false},{"date":"2022-03-31","value":-174987000,"profit":false},{"date":"2023-03-31","value":-545776300,"profit":false},{"date":"2024-03-31","value":-673912000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (801.13K) | (650.98K) | (1.71M) | (5.46M) | (6.73M) | [{"date":"2020-03-31","value":-80113100,"profit":false},{"date":"2021-03-31","value":-65098400,"profit":false},{"date":"2022-03-31","value":-170882700,"profit":false},{"date":"2023-03-31","value":-545749400,"profit":false},{"date":"2024-03-31","value":-673353700,"profit":false}] |
EPS (Diluted) | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
VRAX | |
---|---|
Cash Ratio | 21.26 |
Current Ratio | 25.94 |
Quick Ratio | 25.58 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VRAX | |
---|---|
ROA (LTM) | -49.90% |
ROE (LTM) | -95.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VRAX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.06 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.98 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VRAX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 63.57 |
P/B | 1.15 |
Price/FCF | NM |
EV/R | 35.79 |
EV/Ebitda | 0.42 |
Virax Biolabs Group Limited Ordinary Shares (VRAX) share price today is $2.29
Yes, Indians can buy shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) on Vested. To buy Virax Biolabs Group Limited Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRAX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) via the Vested app. You can start investing in Virax Biolabs Group Limited Ordinary Shares (VRAX) with a minimum investment of $1.
You can invest in shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) via Vested in three simple steps:
The 52-week high price of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $7.63. The 52-week low price of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $0.6.
The price-to-earnings (P/E) ratio of Virax Biolabs Group Limited Ordinary Shares (VRAX) is
The price-to-book (P/B) ratio of Virax Biolabs Group Limited Ordinary Shares (VRAX) is 1.15
The dividend yield of Virax Biolabs Group Limited Ordinary Shares (VRAX) is 0.00%
The market capitalization of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $9.94M
The stock symbol (or ticker) of Virax Biolabs Group Limited Ordinary Shares is VRAX